Search results
Results from the WOW.Com Content Network
The song reached No. 4 on Billboard ' s Best Sellers in Stores survey, along with its flip "The Twelfth of Never", which Mathis initially disliked. [4] The song, released on both 45 RPM and 78 RPM formats, was also included on the 1958 Mathis compilation Johnny's Greatest Hits. The album was certified a gold record on June 5, 1959. [5]
The soundtrack included the Billboard ' s Top 10 single hit song "After All" (composed by Tom Snow and lyrics by Dean Pitchford) performed by Cher and Peter Cetera. The song peaked at #6 on the Billboard Hot 100 in May 1989. Another is the song of the same title as the film sung by Johnny Mathis. Although the film contains other songs, a ...
16 Most Requested Songs is a compilation album by American pop singer Johnny Mathis that was released in 1986 by Columbia Records and ... Chances Are" (Robert Allen ...
John Royce Mathis (born September 30, 1935) is an American singer. He is one of the best-selling recording artists of the 20th century. [2] [3] Starting his career with singles of standard music, Mathis became highly popular as an album artist, with several of his albums achieving gold or platinum status and 73 making the Billboard charts.
Chances Are, a 1981 album by Bob Marley "Chances Are" (song), a 1957 song written by Al Stillman and Robert Allen, popularized by Johnny Mathis "Chances Are", a song by Bob Seger and Martina McBride from Hope Floats: Music from the Motion Picture, 1998 "Chances Are", a song by Invertigo from Forum, 2001
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
"Too Much, Too Little, Too Late" is a song performed by singers Johnny Mathis and Deniece Williams, written by Nat Kipner and John Vallins. The single was a comeback of sorts for Mathis, because his last U.S. top 10 hit had been 1963’s "What Will Mary Say" and his last U.S. #1 hit had been 1957's "Chances Are." [3]
This strong market position generates substantial cash flows that support shareholder returns. Turning to the specifics, the pharmaceutical giant offers investors a 4.3% dividend yield backed by a ...